{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T23:05:03Z","timestamp":1788822303134,"version":"build-2803163510"},"reference-count":28,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2023,3,23]],"date-time":"2023-03-23T00:00:00Z","timestamp":1679529600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"NCI Cancer Center","award":["P30CA016672"],"award-info":[{"award-number":["P30CA016672"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,8,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Despite the clinical benefit of immune checkpoint inhibitors (ICIs), patients with a viral hepatitis have been excluded from clinical trials because of safety concerns. The purpose of this study was to determine the incidence rate of adverse events (AEs) in patients with viral hepatitis who received ICIs for cancer treatment.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Materials and Methods<\/jats:title>\n                  <jats:p>We conducted a retrospective study in patients with cancer and concurrent hepatitis B or C, who had undergone treatment with ICI at MD Anderson Cancer Center from January 1, 2010 to December 31, 2019.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Of the 1076 patients screened, we identified 33 with concurrent hepatitis. All 10 patients with HBV underwent concomitant antiviral therapy during ICI treatment. Sixteen of the 23 patients with HCV received it before the initiation of ICI. The median follow-up time was 33 months (95% CI, 23-45) and the median duration of ICI therapy was 3 months (IQR, 1.9-6.6). Of the 33 patients, 12 (39%) experienced irAEs (immune-related adverse events) of any grade, with 2 (6%) having grade 3 or higher. None of the patients developed hepatitis toxicities.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>ICIs may be a therapeutic option with an acceptable safety profile in patients with cancer and advanced liver disease.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/oncolo\/oyad039","type":"journal-article","created":{"date-parts":[[2023,3,23]],"date-time":"2023-03-23T18:29:25Z","timestamp":1679596165000},"page":"714-721","source":"Crossref","is-referenced-by-count":10,"title":["Safety and Efficacy of Immune Checkpoint Inhibitors in Patients with Cancer and Viral Hepatitis: The MD Anderson Cancer Center Experience"],"prefix":"10.1093","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9396-7864","authenticated-orcid":false,"given":"Mirella","family":"Nardo","sequence":"first","affiliation":[{"name":"Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center , Houston, TX , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bulent","family":"Yilmaz","sequence":"additional","affiliation":[{"name":"Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center , Houston, TX , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blessie Elizabeth","family":"Nelson","sequence":"additional","affiliation":[{"name":"Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center , Houston, TX , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harrys A","family":"Torres","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center , Houston, TX , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lan Sun","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Genitourinary Medicine, The University of Texas MD Anderson Cancer Center , Houston, TX , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno Palma","family":"Granwehr","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center , Houston, TX , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8688-4104","authenticated-orcid":false,"given":"Juhee","family":"Song","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, The University of Texas MD Anderson Cancer Center , Houston, TX , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanna R F","family":"Dalla Pria","sequence":"additional","affiliation":[{"name":"Department of Radiology, The University of Texas MD Anderson Cancer Center , Houston, TX , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Van A","family":"Trinh","sequence":"additional","affiliation":[{"name":"Department of Melanoma Medicine, The University of Texas MD Anderson Cancer Center , Houston, TX , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabella C","family":"Glitza Oliva","sequence":"additional","affiliation":[{"name":"Department of Melanoma Medicine, The University of Texas MD Anderson Cancer Center , Houston, TX , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sapna P","family":"Patel","sequence":"additional","affiliation":[{"name":"Department of Melanoma Medicine, The University of Texas MD Anderson Cancer Center , Houston, TX , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nizar M","family":"Tannir","sequence":"additional","affiliation":[{"name":"Department of Genitourinary Medicine, The University of Texas MD Anderson Cancer Center , Houston, TX , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed Omar","family":"Kaseb","sequence":"additional","affiliation":[{"name":"Department of Genitourinary Medicine, The University of Texas MD Anderson Cancer Center , Houston, TX , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet","family":"Altan","sequence":"additional","affiliation":[{"name":"Department of Genitourinary Medicine, The University of Texas MD Anderson Cancer Center , Houston, TX , USA"},{"name":"Department of Thoracic\/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center , Houston TX , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunyoung S","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Medicine, The University of Texas MD Anderson Cancer Center , Houston, TX , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ethan","family":"Miller","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Medicine, The University of Texas MD Anderson Cancer Center , Houston, TX , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Medicine, The University of Texas MD Anderson Cancer Center , Houston, TX , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bettzy A","family":"Stephen","sequence":"additional","affiliation":[{"name":"Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center , Houston, TX , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aung","family":"Naing","sequence":"additional","affiliation":[{"name":"Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center , Houston, TX , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,3,23]]},"reference":[{"key":"2023080322074310100_CIT0001","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"N Engl J Med."},{"key":"2023080322074310100_CIT0002","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1038\/bjc.2015.124","article-title":"Anti-programmed cell death protein-1\/ligand-1 therapy in different cancers","volume":"112","author":"Homet Moreno","year":"2015","journal-title":"Br J Cancer."},{"key":"2023080322074310100_CIT0003","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in previously untreated melanoma without BRAF mutation","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med."},{"key":"2023080322074310100_CIT0004","doi-asserted-by":"crossref","first-page":"53","DOI":"10.4103\/JIPO.JIPO_15_19","article-title":"Cancer immunotherapy for the immunosuppressed: dissecting the conundrum of safety and efficacy","volume":"2","author":"Hajjar","year":"2019","journal-title":"J Immunother Precis Oncol."},{"key":"2023080322074310100_CIT0005","doi-asserted-by":"crossref","first-page":"33","DOI":"10.36401\/JIPO-21-X1","article-title":"The immune system, cancer, and pathogens: it takes three to tango!","volume":"4","author":"Hajjar","year":"2021","journal-title":"J Immunother Precis Oncol."},{"key":"2023080322074310100_CIT0006","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.jhep.2013.02.022","article-title":"A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C","volume":"59","author":"Sangro","year":"2013","journal-title":"J Hepatol."},{"key":"2023080322074310100_CIT0007","doi-asserted-by":"crossref","first-page":"e827","DOI":"10.1002\/onco.13739","article-title":"Safety of immune checkpoint inhibitors in patients with cancer and hepatitis C virus infection","volume":"26","author":"Alkrekshi","year":"2021","journal-title":"Oncologist."},{"key":"2023080322074310100_CIT0008","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1016\/S0140-6736(17)31046-2","article-title":"Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1\/2 dose escalation and expansion trial","volume":"389","author":"El-Khoueiry","year":"2017","journal-title":"Lancet."},{"key":"2023080322074310100_CIT0009","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/S1470-2045(18)30351-6","article-title":"Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial","volume":"19","author":"Zhu","year":"2018","journal-title":"Lancet Oncol."},{"key":"2023080322074310100_CIT0010","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S1470-2045(21)00604-5","article-title":"Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial","volume":"23","author":"Yau","year":"2022","journal-title":"Lancet Oncol."},{"key":"2023080322074310100_CIT0011"},{"key":"2023080322074310100_CIT0012","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"67","author":"Terrault","year":"2018","journal-title":"Hepatology."},{"key":"2023080322074310100_CIT0013","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1002\/hep.31060","article-title":"Hepatitis C Guidance 2019 Update: American Association for the Study of Liver Diseases-Infectious Diseases Society of America recommendations for testing, managing, and treating hepatitis C virus infection","volume":"71","author":"Ghany","year":"2020","journal-title":"Hepatology."},{"key":"2023080322074310100_CIT0014","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/hep.29344","article-title":"Hepatitis C virus reactivation in patients receiving cancer treatment: a prospective observational study","volume":"67","author":"Torres","year":"2018","journal-title":"Hepatology."},{"key":"2023080322074310100_CIT0015","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1056\/NEJMra052270","article-title":"Drug-related hepatotoxicity","volume":"354","author":"Navarro","year":"2006","journal-title":"N Engl J Med."},{"key":"2023080322074310100_CIT0016","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer."},{"key":"2023080322074310100_CIT0017","doi-asserted-by":"crossref","first-page":"3936","DOI":"10.1158\/1078-0432.CCR-13-0895","article-title":"Developing a common language for tumor response to immunotherapy: immune-related response criteria using unidimensional measurements","volume":"19","author":"Nishino","year":"2013","journal-title":"Clin Cancer Res."},{"key":"2023080322074310100_CIT0018","doi-asserted-by":"crossref","first-page":"53","DOI":"10.36401\/JIPO-20-19","article-title":"Reactivation of hepatitis B virus among patients with cancer receiving immunotherapy","volume":"4","author":"Hwang","year":"2021","journal-title":"J Immunother Precis Oncol."},{"key":"2023080322074310100_CIT0019","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1097\/CJI.0000000000000358","article-title":"Hepatitis B virus reactivation in cancer patients treated with immune checkpoint inhibitors","volume":"44","author":"Burns","year":"2021","journal-title":"J Immunother."},{"key":"2023080322074310100_CIT0020","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1200\/JCO.2015.61.3745","article-title":"Hepatitis B virus screening for patients with cancer before therapy: American Society of Clinical Oncology Provisional clinical opinion update","volume":"33","author":"Hwang","year":"2015","journal-title":"J Clin Oncol."},{"key":"2023080322074310100_CIT0021","doi-asserted-by":"crossref","first-page":"e1000313","DOI":"10.1371\/journal.ppat.1000313","article-title":"Synergistic reversal of intrahepatic HCV-specific CD8 T cell exhaustion by combined PD-1\/CTLA-4 blockade","volume":"5","author":"Nakamoto","year":"2009","journal-title":"PLoS Pathog."},{"key":"2023080322074310100_CIT0022","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.annonc.2019.10.008","article-title":"Adverse event profile for immunotherapy agents compared with chemotherapy in solid organ tumors: a systematic review and meta-analysis of randomized clinical trials","volume":"31","author":"Magee","year":"2020","journal-title":"Ann Oncol."},{"key":"2023080322074310100_CIT0023","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1007\/s10637-017-0534-0","article-title":"Incidence of immune-related adverse events and its association with treatment outcomes: the MD Anderson Cancer Center experience","volume":"36","author":"Fujii","year":"2018","journal-title":"Invest New Drugs."},{"key":"2023080322074310100_CIT0024","doi-asserted-by":"crossref","first-page":"3807","DOI":"10.1200\/JCO.2017.73.2289","article-title":"Efficacy and safety outcomes in patients with advanced melanoma who discontinued treatment with nivolumab and ipilimumab because of adverse events: a pooled analysis of randomized phase II and III trials","volume":"35","author":"Schadendorf","year":"2017","journal-title":"J Clin Oncol."},{"key":"2023080322074310100_CIT0025","doi-asserted-by":"crossref","first-page":"3193","DOI":"10.1200\/JCO.2015.60.8448","article-title":"Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at memorial sloan kettering cancer center","volume":"33","author":"Horvat","year":"2015","journal-title":"J Clin Oncol."},{"key":"2023080322074310100_CIT0026","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.ejca.2020.12.012","article-title":"Effect of corticosteroids on the outcome of patients with advanced non-small cell lung cancer treated with immune-checkpoint inhibitors","volume":"145","author":"Skribek","year":"2021","journal-title":"Eur J Cancer."},{"key":"2023080322074310100_CIT0027","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1016\/j.jhep.2019.06.028","article-title":"Anti-PD-1 blockade with nivolumab with and without therapeutic vaccination for virally suppressed chronic hepatitis B: a pilot study","volume":"71","author":"Gane","year":"2019","journal-title":"J Hepatol."},{"key":"2023080322074310100_CIT0028","doi-asserted-by":"crossref","first-page":"e001754","DOI":"10.1136\/jitc-2020-001754","article-title":"Strategies for improving the management of immune-related adverse events","volume":"8","author":"Naing","year":"2020","journal-title":"J ImmunoTher Cancer."}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/28\/8\/714\/51034794\/oyad039.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/28\/8\/714\/51034794\/oyad039.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,3]],"date-time":"2023-08-03T22:08:59Z","timestamp":1691100539000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/28\/8\/714\/7084884"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,23]]},"references-count":28,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2023,3,23]]},"published-print":{"date-parts":[[2023,8,3]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyad039","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,8,1]]},"published":{"date-parts":[[2023,3,23]]}}}